Is This How Drugmakers Will Kill Biosimilars?
Pfizer (NYSE: PFE) has filed a lawsuit accusing Johnson & Johnson (NYSE: JNJ) of strong-arming insurers into excluding its Remicade biosimilar, Inflectra, from their reimbursement lists. If drugmakers start to employ this strategy widely, it could have big implications on the peak market potential for biosimilars industrywide.
In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Michael Douglass and contributor Todd Campbell offer some insights into Pfizer's dispute with Johnson & Johnson, and discuss more broadly what the suit may mean to investors.
A full transcript follows the video.
Source: Fool.com
Pfizer Inc. Aktie
21,71 €
0,79 %
Mehrere Buy-Einschätzungen für Pfizer Inc., die die Sell-Einschätzungen übersteigen.
Ein Kursziel von 29 € für Pfizer Inc. würde eine Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 21.71 € bedeuten.
